We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Celestial Labs is a drone display company that combines advanced technology with organic performance. The company's proprietary 'Skytheatre' display is a dynamic, safe and green alternative to carbon-intensive fireworks and represents a new frontier for the live event industry. Composed of a creative collective of award-winning filmmakers, musicians, developers, entrepreneurs, and storytellers, the company is constantly pushing the boundaries of drone display innovation, where technology meets imagination. The Human Support division of Celestial is a not-for-profit initiative that aims to lift the spirits of those who witness Celestial's displays whilst imparting crucial information. The company aims to enlist the support and guidance of city leadership partners, industrial conglomerates, and seek grant funding.
days to go: Stretch investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
SuperCarers is an online platform that helps families to find trusted carers living in their local area. SuperCarers do not have the high overhead costs of agencies and therefore enable supercarers to be paid significantly more than the national living wage. 
days to go: Expired investment: £1,079,495
A personal fitness app that aims to provide affordable and accessible training on demand. Auro offers classes for specific needs via an audio coach; from increasing stamina, to losing weight. Each class includes a motivational trainer with a dedicated playlist. The company also utilises artificial intelligence to personalise workout programmes for each user and has filed a patent for this technology. Auro’s app has already received more than 10k downloads and is backed by top investors, such as the founders of LoveFilm, Zoopla and Passion Capital. The company is raising funds to scale the business further in the UK and expand into Europe.
days to go: Expired investment: £262,230
GP Nutrition is a nutrition company that creates products meant to deliver sustainable weight loss. This award-winning company was created by Gabriela Peacock, a celebrity nutritionist. It has 13,000 global customers who have bought more than 30,000 packs. In June'19, the company reached trading of £50k per month. It has produced 22 products that are now sold in 30 countries. GP Nutrition has delivered revenue of £377k and an EBITDA of £813,389. Nutrition's vision is to solve the 95% failure rate of diets in the USA and the UK.
days to go: Expired investment: £309,890
Riders can enjoy indoor cycling within a boutique fitness studio. In the past 6 years, Boom Cycle have opened five sites are now seeking funds to expand their portfolio. To date, Boom Cycle has acquired over £4.1m from private investors and in 2017 spent £2.1m on developing two flagship studios. The company has experienced attendance growth of 47% YoY, as well as a 77% increase in revenue YoY.
days to go: Expired investment: £805,260
Aiming to improve the health and well-being of the UK by incorporating spa and beauty treatments into everyday life. PURE is a profitable business that currently runs 8 urban spas across Great Britain, as well as selling their own range of natural products and treatments for skincare to be used at home. Over 100k clients a year have used PURE's services, with 40% of appointments being booked via the company's website and mobile app. This has resulted in sales of £2.9m in 2017, with group revenue increasing by more than 21% in the year-to-date. Investments will be used to open in more locations, develop more products and expand the PURE Beauty Zone marketplace for independent health and beauty businesses to sell their products in PURE's spas and on their website.
days to go: Expired investment: £72,650
Speeding up access to mental health treatments by using electronic forms and universal communication tools. Thalamos has created a solution for multiple health entities such as the NHS, social services, charities, etc. The company aims to move these entities away from pen and paper, to an easy-to-use online platform, as manual entries are prone to information and data being misplaced, as well as prone to errors. Thalamos's cloud platform will enable psychiatrists to reduce their clinical and information governance risk, whilst helping to continuously improve their patients' recovery process. The product will be subscription-based from £600 per year, which can be paid monthly and is in-line with other professional services.
days to go: Expired investment: £171,548
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph